Novo signs new license deal
Novo Nordisk has struck a license deal with a US-based biotech company, which could be worth USD 295 million plus royalties.
BY STEFAN SINGH KAILAY
For the second time in less than a week, Denmark’s Novo Nordisk has signed a license agreement with a biotech company. US-based biotech player Xoma says Tuesday that it has entered into a global development and commercialization partnership with Novo Nordisk.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Nordisk enters partnership with Belgian company
For abonnenter
Novo to invest DKK 2 billion and create 450 jobs
For abonnenter
Novo targets workers from Germany and Poland
For abonnenter
